A retrospective cohort linked the Ohio cancer registry to Medicaid claims for 1,988 patients aged 18 to 65 with non-metastatic ER-positive, HER2-negative breast cancer. Molecular profiling within six months of diagnosis was recorded for 752 of them, 37.8%. Receipt was lower for regional than localised disease (aOR 0.35) and for Black than White women (aOR 0.72).
Why it is interesting: Testing that informs precision oncology reached under two in five, and varied by stage and race.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.